Pantoprazole may improve beta cell function and diabetes mellitus

İnci, Fatih; Atmaca, Murat; Öztürk, Mustafa; Yıldız, Saliha; Köçeroğlu, Ruşen; Şekeroğlu, Ramazan; İpekçi, Süleyman Hilmi; Kebapçılar, Levent

doi:10.1007/s40618-013-0040-y

Cited by 14 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The elevated fasting gastrin levels are probably consistent with the fact that all subjects received prophylactic PPI treatment 7 days prior to the first experimental day, and, thus, may reflect PPI‐induced hypergastrinaemia …”

Section: Discussionmentioning

confidence: 60%

The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes

Rohde

Federspiel

Vilmann

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 60%

The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes

Rohde

Federspiel

Vilmann

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Moreover, recent data have shown that patients with upper gastrointestinal disease exposed to PPIs for 5 years have a lower risk of developing type 2 diabetes 45. An improvement of beta cells’ function after a 12 weeks PPI treatment of patients with and without diabetes suggests a potential protective role in glucose homeostasis 46. Besides, a possible effect on glycaemic parameters, this mentioned hypothesis cannot explain a spontaneous hypoglycaemia.…”

Section: Discussionmentioning

confidence: 97%

Impact of drugs on hypoglycaemia in hospitalised patients

Vandenberghe

Challet

Maitrejean³

et al. 2018

Eur J Hosp Pharm

View full text Add to dashboard Cite

ObjectivesHospital admission rates for hypoglycaemia now exceed those for hyperglycaemias among older adults. A growing number of reports associating hypoglycaemia with non-antidiabetic drugs have been published. Clinical pharmacists are often faced with hypoglycaemia in patients taking multiple medications. This study assessed the potential relationship between prescribed drugs and episodes of hypoglycaemia during hospitalisation.MethodsPoint-of-care blood glucose values and prescribed drugs were analysed in patients admitted to a regional hospital. Hypoglycaemia cases were defined as patients with at least one hypoglycaemic event (random glucose value ≤3.9 mmol/L), and normoglycaemic cases as those with random glucose concentrations within the range of 4.5–5.8 mmol/L. Analyses were carried out using multivariate logistic regressions and Cox proportional hazard models.Results373 patients (53% males; median age=74 years) were included in the analysis and of these, 64 (17%) had at least one hypoglycaemic event. Patients who experienced a hypoglycaemic event had a longer length of stay (median=10 vs 7 days, p<0.01) and a higher rate of antidiabetic drugs prescription (83% vs 37%, p<0.01). The number of non-antidiabetic drugs was associated with an increased risk of hypoglycaemia during hospitalisation (HR 2.3, 95% CI 1.4 to 4, p<0.01). After adjusting by confounders, heparin and pantoprazole were found to be associated with hypoglycaemia.ConclusionsThe relationship between hypoglycaemia and polypharmacy reinforces the advice to limit polymedication as much as possible, especially in elderly patients. This result underlines the potential involvement of clinical pharmacists with the aim to reduce the risk of hypoglycaemia during hospitalisation.

show abstract

“…To the best of our knowledge, the effect of PPI on glucose levels in non-diabetic subjects was previously assessed in only one study 15 that reported lower fasting glycaemia and higher concentrations of insulin after 12 weeks of pantoprazole administration in 38 healthy volunteers. In our hands, chronic PPI use was unrelated to glucose levels - either fasting or 2-h postload.…”

Section: Discussionmentioning

confidence: 99%

No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study

et al. 2017

View full text Add to dashboard Cite

Background: Proton pump inhibitor (PPI) use was reportedly associated with an excess of adverse cardiovascular (CV) events, thus making their systemic effects relevant to public health. PPIs reduce gastric acid secretion, causing increased gastrin release. Gastrin stimulates β-cell neogenesis and enhances insulin release, exerting an incretin-like effect. Our aim was to assess, if PPI usage is associated with altered glycaemia in patients with CV disease.Methods: We retrospectively analyzed medical records of 102 subjects (80 with ischemic heart disease) who underwent a routine oral glucose tolerance test while hospitalized in a cardiology department. Fasting and 2-h postload glucose levels were compared according to PPI use for ≥1 month prior to admission.Results: Compared to 51 subjects without PPIs, those on a PPI were older, more frequently male, had a lower body-mass index and a tendency to a worse renal function. PPI users and non-users exhibited similar glucose levels at baseline (5.6 ± 0.9 vs. 5.5 ± 1.1 mmol/l, P = 0.5) and 2-hrs post glucose intake (9.8 ± 3.0 vs. 9.9 ± 3.4 mmol/l, P = 0.9). This was consistent across subgroups stratified by gender or diabetes status. The results were substantially unchanged after adjustment for different characteristics of subjects with and without PPIs.Conclusions: PPI use does not appear associated with altered glycaemia in subjects with CV disease. Unchanged glucose tolerance despite PPI usage may result from simultaneous activation of pathways that counteract the putative PPI-induced incretin-like effect.

show abstract

Pantoprazole may improve beta cell function and diabetes mellitus

Cited by 14 publications

References 18 publications

The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes

The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes

Impact of drugs on hypoglycaemia in hospitalised patients

No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study

Contact Info

Product

Resources

About